The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 5, 2023 | Baker Bros. Advisors (GP) LLC | Director, 10% Owner | Option exercise(X) | 536K | — | — |
| Oct 5, 2023 | Baker Bros. Advisors (GP) LLC | Director, 10% Owner | Option exercise(X) | 57K | — | — |
| Oct 5, 2023 | Baker Bros. Advisors (GP) LLC | Director, 10% Owner | Option exercise(X) | 57K | — | $0 |
| Oct 5, 2023 | Baker Bros. Advisors (GP) LLC | Director, 10% Owner | Option exercise(X) | 536K | — | $0 |
| Aug 17, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 61K | $0.69 | $42K |
| Aug 17, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 5K | $0.69 | $3K |
| Aug 17, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 93K | $0.69 | $64K |
| Aug 17, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 8K | $0.69 | $5K |
| Aug 16, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 4K | $0.68 | $3K |
| Aug 16, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 17K | $0.68 | $12K |
| Aug 16, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 208K | $0.68 | $141K |
| Aug 16, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 366 | $0.68 | $249 |
| Aug 15, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 4K | $0.67 | $3K |
| Aug 15, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 144K | $0.63 | $90K |
| Aug 15, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 1.7M | $0.63 | $1.1M |
| Aug 15, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 358 | $0.67 | $240 |
| Aug 11, 2023 | Smith Sean Michael | Interim CFO, Prin Acct Off | Sell(S) | 1K | $0.62 | $820 |
| Aug 10, 2023 | Smith Sean Michael | Interim CFO, Prin Acct Off | Option exercise(M) | 5K | — | $0 |
| Aug 10, 2023 | Smith Sean Michael | Interim CFO, Prin Acct Off | Option exercise(M) | 5K | — | $0 |
| Jun 8, 2023 | Babler Martin | Director | Grant(A) | 25K | — | $0 |
| Jun 8, 2023 | Lavelle Erin | Director | Grant(A) | 25K | — | $0 |
| Jun 8, 2023 | Noonberg Sarah B. | Director | Grant(A) | 25K | — | $0 |
| Jun 8, 2023 | Palekar Rohan | Director | Grant(A) | 25K | — | $0 |
| Jun 8, 2023 | Simpson Todd E | Director | Grant(A) | 25K | — | $0 |
| Jun 8, 2023 | Baker Brothers Life Sciences LP | Director | Grant(A) | 25K | — | $0 |
| Jun 8, 2023 | Baker Brothers Life Sciences LP | Director | Grant(A) | 25K | — | $0 |
| Apr 3, 2023 | Patel Priti | Insider | Sell(S) | 4K | $0.69 | $3K |
| Mar 31, 2023 | Patel Priti | Insider | Option exercise(M) | 10K | — | $0 |
| Mar 31, 2023 | Patel Priti | Insider | Option exercise(M) | 10K | — | $0 |
| Feb 2, 2023 | Patel Priti | Chief Medical Officer | Sell(S) | 14K | $0.60 | $9K |
| Feb 2, 2023 | Smith Sean Michael | Principal Accounting Officer | Sell(S) | 3K | $0.60 | $2K |
| Feb 1, 2023 | Patel Priti | Chief Medical Officer | Option exercise(M) | 35K | — | $0 |
| Feb 1, 2023 | Patel Priti | Chief Medical Officer | Option exercise(M) | 35K | — | $0 |
| Feb 1, 2023 | Smith Sean Michael | Principal Accounting Officer | Option exercise(M) | 13K | — | $0 |
| Feb 1, 2023 | Smith Sean Michael | Principal Accounting Officer | Option exercise(M) | 13K | — | $0 |
| Aug 10, 2022 | Smith Sean Michael | Principal Accounting Officer | Sell(S) | 2K | $0.99 | $2K |
| Aug 10, 2022 | Smith Sean Michael | Principal Accounting Officer | Option exercise(M) | 5K | — | $0 |
| Aug 10, 2022 | Smith Sean Michael | Principal Accounting Officer | Option exercise(M) | 5K | — | $0 |
| Aug 2, 2022 | Cochener Donna | General Counsel, SVP Legal | Grant(A) | 100K | — | $0 |
| Aug 2, 2022 | Drachman Jonathan G | President and CEO, Director | Grant(A) | 350K | — | $0 |
| Aug 2, 2022 | Patel Priti | Chief Medical Officer | Grant(A) | 250K | — | $0 |
| Aug 2, 2022 | Smith Sean Michael | Principal Accounting Officer | Grant(A) | 150K | — | $0 |
| Aug 2, 2022 | Walkey Carl | Senior Vice President | Grant(A) | 150K | — | $0 |
| May 12, 2022 | Baker Felix | Director | Grant(A) | 25K | — | $0 |
| May 12, 2022 | Babler Martin | Director | Grant(A) | 25K | — | $0 |
| May 12, 2022 | Lavelle Erin | Director | Grant(A) | 25K | — | $0 |
| May 12, 2022 | Noonberg Sarah B. | Director | Grant(A) | 25K | — | $0 |
| May 12, 2022 | Palekar Rohan | Director | Grant(A) | 25K | — | $0 |
| May 12, 2022 | Simpson Todd E | Director | Grant(A) | 25K | — | $0 |
| May 2, 2022 | Patel Priti | Chief Medical Officer | Sell(S) | 6K | $1.22 | $7K |
| Apr 30, 2022 | Patel Priti | Chief Medical Officer | Option exercise(M) | 10K | — | $0 |
| Apr 30, 2022 | Patel Priti | Chief Medical Officer | Option exercise(M) | 10K | — | $0 |
| Mar 14, 2022 | Cochener Donna | General Counsel, SVP Legal | Grant(A) | 400K | — | $0 |
| Mar 2, 2022 | Smith Sean Michael | Principal Accounting Officer | Grant(A) | 80K | — | $0 |
| Mar 2, 2022 | Palekar Rohan | Director | Grant(A) | 50K | — | $0 |
| Feb 1, 2022 | Ho Robert | Chief Financial Officer | Grant(A) | 70K | — | $0 |
| Feb 1, 2022 | Patel Priti | Chief Medical Officer | Grant(A) | 70K | — | $0 |
| Feb 1, 2022 | Walkey Carl | Senior Vice President | Grant(A) | 55K | — | $0 |
| Aug 25, 2021 | Drachman Jonathan G | President and CEO, Director | Buy(P) | 25K | $6.45 | $161K |
| Aug 25, 2021 | Drachman Jonathan G | President and CEO, Director | Buy(P) | 25K | $6.45 | $161K |
| Aug 24, 2021 | Drachman Jonathan G | President and CEO, Director | Buy(P) | 100K | $6.11 | $611K |
| Aug 3, 2021 | Walkey Carl | Senior Vice President | Grant(A) | 100K | — | $0 |
| Aug 3, 2021 | Vance Holly | General Counsel | Grant(A) | 100K | — | $0 |
| Aug 3, 2021 | Patel Priti | Chief Medical Officer | Grant(A) | 50K | — | $0 |
| Aug 3, 2021 | Ho Robert | Chief Financial Officer | Grant(A) | 190K | — | $0 |
| Aug 3, 2021 | Drachman Jonathan G | President and CEO, Director | Grant(A) | 400K | — | $0 |
| Jun 16, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 600 | $10.19 | $6K |
| Jun 9, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 650 | $10.82 | $7K |
| Jun 8, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 600 | $11.00 | $7K |
| Jun 4, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 600 | $10.00 | $6K |
| Jun 4, 2021 | Drachman Jonathan G | President and CEO, Director | Buy(P) | 10K | $9.61 | $96K |
| Jun 3, 2021 | Drachman Jonathan G | President and CEO, Director | Buy(P) | 40K | $9.48 | $379K |
| May 26, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 600 | $10.00 | $6K |
| May 19, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 600 | $10.63 | $6K |
| May 12, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 1K | $11.09 | $13K |
| May 11, 2021 | Williams Lewis T | Director | Grant(A) | 25K | — | $0 |
| May 11, 2021 | Simpson Todd E | Director | Grant(A) | 25K | — | $0 |
| May 11, 2021 | Noonberg Sarah B. | Director | Grant(A) | 25K | — | $0 |
| May 11, 2021 | Lavelle Erin M. | Director | Grant(A) | 25K | — | $0 |
| May 11, 2021 | Babler Martin | Director | Grant(A) | 25K | — | $0 |
| May 5, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 1K | $11.30 | $14K |
| Apr 30, 2021 | Patel Priti | Chief Medical Officer | Grant(A) | 475K | — | $0 |
| Apr 30, 2021 | Patel Priti | Chief Medical Officer | Grant(A) | 20K | — | $0 |
| Apr 28, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 2K | $12.58 | $30K |
| Apr 26, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 600 | $13.00 | $8K |
| Apr 21, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 2K | $11.98 | $22K |
| Apr 14, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 2K | $12.22 | $22K |
| Apr 7, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 2K | $12.02 | $22K |
| Apr 5, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 600 | $13.00 | $8K |
| Mar 31, 2021 | Walkey Carl | Senior Vice President | Sell(S) | 2K | $11.96 | $22K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-14. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).